Prevention of low dose streptozotocin induced diabetes by muramyl dipeptide.
The objective of the present investigation was to evaluate the effect of the synthetic immunomodulator MDP on an experimentally induced diabetes. It has been previously demonstrated that a single high dose of streptozotocin (STZ) induces hyperglycemia by direct destruction of pancreatic beta-cells. MDP had no effect on the diabetes induced by high dose STZ injection. However, MDP partially protected mice against the toxicity of STZ. In contrast to the first model, repeated low dosages of STZ have been shown to induce hyperglycemia due to autoimmune destruction of beta-cells. Large dosages of MDP given before these low dosages of STZ markedly decreased the diabetogenic effect of STZ. It is proposed that this protection is due to the immunosuppressive activity of MDP.
Leclerc
C
C
Institut Pasteur, Department of Immunology, Paris, France.
Deriaud
E
E
Schutze
M P
MP
Chedid
L
L
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose; D003921:Diabetes Mellitus, Experimental / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D051379:Mice; D013311:Streptozocin / Q000633:toxicity*
D001786:Blood Glucose; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D013311:Streptozocin